NCT05793151 (ENDURE) is a NA clinical trial of ENDURE in Head and Neck Cancer, sponsored by Medical University of South Carolina.

Who is sponsoring NCT05793151?

NCT05793151 is sponsored by Medical University of South Carolina.

What drugs are being tested in NCT05793151?

Interventions in NCT05793151: ENDURE.

What condition does NCT05793151 study?

NCT05793151 studies Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer, Oral Cavity Cancer, Larynx Cancer.

Is NCT05793151 still recruiting?

NCT05793151 is currently recruiting now. Last updated 11 December 2025.

Last reviewed 2025-12-11 · How we verify

NCT05793151: ENDURE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy

Recruiting now NA Last updated 11 December 2025

What this trial tests

NA trial testing ENDURE in Head and Neck Cancer in 532 participants. Currently enrolling.

Timeline

30 October 2023

Primary endpoint
30 March 2028

30 March 2028

Quick facts

Lead sponsor	Medical University of South Carolina
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	none
Primary purpose	health services research
Enrollment	532
Start date	30 October 2023
Primary completion	30 March 2028
Estimated completion	30 March 2028
Sites	4 locations across United States

Drugs / interventions tested

ENDURE

Conditions studied

Head and Neck Cancer — all drugs for Head and Neck Cancer →
Head and Neck Squamous Cell Carcinoma — all drugs for Head and Neck Squamous Cell Carcinoma →
Oropharynx Cancer — all drugs for Oropharynx Cancer →
Oral Cavity Cancer — all drugs for Oral Cavity Cancer →

Sponsor

Medical University of South Carolina

Who can join

18 and older, any sex, with Head and Neck Cancer or Head and Neck Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to compare the effectiveness of a navigation-based multilevel intervention (ENDURE) with treatment as usual (TAU) to improve the initiation of guideline-adherent postoperative radiation therapy among patients with head and neck cancer. The main questions the trial aims to answer are: 1. Does ENDURE improve initiation of timely PORT relative to treatment as usual? 2. What are the mechanisms through which ENDURE improves timeliness to treatment? 3. What are the barriers and facilitators to the implementation of ENDURE into routine clinical care?

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Patient Navigation in Cancer Treatment: A Systematic Review.
Chen M, Wu VS, Falk D, Cheatham C, et al · · 2024 · cited 72× · PMID 38581470 · DOI 10.1007/s11912-024-01514-9
Changing What Can Be Changed: Validating Navigation as Essential Care in Modern Oncology.
Schwartz DL, Brett C, Gleysteen JP. · · 2025 · PMID 40138613 · DOI 10.1200/op-25-00020

Verify or expand the search:

Other recruiting trials for Head and Neck Cancer

Currently open trials in the same condition.

NCT07318220 — Prehabilitation Protocol for Head and Neck Cancer Patients · NA · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07467083 — Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Unde · Phase 3 · recruiting
NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting

Other Medical University of South Carolina trials

Trials by the same sponsor.

NCT06491264 — Multiparameter Optimized tES for Memory in Aging · NA · withdrawn
NCT07513389 — Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION) · Phase 2 · not yet recruiting
NCT03101917 — Microtable® Method for Cochlear Implantation Investigational Device Exemption (IDE) · NA · not yet recruiting
NCT07149207 — Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors · Phase 2 · recruiting
NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05793151 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of South Carolina
Last refreshed: 11 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05793151.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing